

# Turkmenistan

Population 2015

5.4 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.46 (0.42–0.49)	8.5 (7.8–9.2)
Mortality (HIV+TB only)	0 (–)	0 (–)
Incidence (includes HIV+TB)	3.8 (2.9–4.8)	70 (54–88)
Incidence (HIV+TB only)		
Incidence (MDR/RR-TB)**	0.85 (0.67–1)	16 (12–19)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	0.18 (0.087–0.27)	1.1 (0.59–1.7)	1.3 (0.67–1.9)
Males	0.19 (0.12–0.26)	2.3 (1.7–2.8)	2.5 (1.8–3.1)
Total	0.37 (0.25–0.49)	3.4 (2.9–3.9)	3.8 (2.9–4.8)

TB case notifications, 2015	
Total cases notified	3 309
Total new and relapse	3 028
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	
- % pulmonary	50%
- % bacteriologically confirmed among pulmonary	69%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	80% (64–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.12 (0.1–0.16)

TB/HIV care in new and relapse TB patients, 2015		Number	(%)
Patients with known HIV-status who are HIV-positive		0	
- on antiretroviral therapy			

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			360 (310–420)
Estimated % of TB cases with MDR/RR-TB	14% (11–17)	38% (31–46)	
% notified tested for rifampicin resistance			
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: 270, XDR-TB:	
Patients started on treatment ****		MDR/RR-TB: 270, XDR-TB:	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	85%	2 122
Previously treated cases, excluding relapse, registered in 2014	65%	143
HIV-positive TB cases, all types, registered in 2014		0
MDR/RR-TB cases started on second-line treatment in 2013	0%	81
XDR-TB cases started on second-line treatment in 2013		

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)

